No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MRK250117P101000
- 1.80
- +0.46+34.33%
15min DelayClose Jan 14 16:00 ET
1.80High1.35Low
1.35Open1.34Pre Close9 Volume358 Open Interest101.00Strike Price1.39KTurnover23.60%IV0.45%PremiumJan 17, 2025Expiry Date1.35Intrinsic Value100Multiplier2DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type-0.7411Delta0.1627Gamma60.95Leverage Ratio-0.1206Theta-0.0047Rho-45.17Eff Leverage0.0275Vega
Intraday
- 5D
- Daily
News
Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value
Boeing, NVIDIA Corp. Share Losses Lead Dow's 113-Point Drop
Merck Speeds Up Launch of New Keytruda Version as Patent Expiration Nears -- Barrons.com
BMO Capital Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $105
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150
Merck & Co.'s Accelerated Keytruda Launch and Strategic Updates Bolster Long-term Growth Prospects